Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.56 | N/A | +2.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.56 | N/A | +2.34% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautiously optimistic outlook, emphasizing their commitment to innovation. They acknowledged some challenges but remained focused on long-term growth.
Management highlighted the strong performance in their key therapeutic areas.
They expressed confidence in their pipeline but acknowledged market challenges.
Amgen's earnings report showed a positive surprise in EPS, which indicates better-than-expected profitability. However, the stock fell by 1.02%, likely due to the lack of revenue details and no guidance for the future. Investors may be cautious given the absence of specific forward-looking statements.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SOUTHERN COPPER CORP
Apr 29, 2019